Yesim Dargaud
Hematology — Hospices Civils de Lyon, France
Yesim Dargaud
LeadR Profile
Hematology
Subspecialties: Genetics - Biochemistry - Cardiology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1999 - 2026
Number : 247
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Implications of Glucagon-Like Peptide-1 Signaling for Hemophilic Arthropathy, Joint Inflammation, and Cartilage Degeneration: A Narrative Review. glucagon-like peptide 1, joint diseases, hemorrhage, arthritis, hemophilia a, glucagon, cartilage, glucagon-like peptides | Haemophilia | 2026 | 0 |
| Effect of a short questionnaire (7VTE-Quest) on venous thromboembolism to guide education during consultation. anticoagulants, thromboembolism, mental recall, anti-inflammatory agents, non-steroidal, contraindications, therapeutics, venous thromboembolism, education, patient education as topic | Medicine (Baltimore) | 2026 | 0 |
| Patient Preferences for the Treatment of Haemophilia A and B in France. safety, patient preference, hemophilia a, therapeutics | Haemophilia | 2026 | 0 |
| Acquired hemophilia A: an illustrated review based on the French National Guidelines. partial thromboplastin time, hemorrhage, hemophilia a, therapeutics | Res Pract Thromb Haemost | 2026 | 0 |
| From Bleeding Control to Health: Implementing Multidimensional and Multidisciplinary Hemophilia Care Into the Era of Therapeutic Innovation. hemorrhage, hemophilia a, therapeutics | Haemophilia | 2026 | 0 |
Clinical Studies 18
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
5 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People with Hemophilia A 2025-522435-33-00 — safety, hemophilia a, pharmacokinetics | Phase 3 | Recruiting | 2026 |
| A Trial to Learn if REGV131 LNP1265 is Safe and Works to Help the Body Make Clotting Factor in Adult Patients with Hemophilia B 2023-507260-40-00 — factor ix, genes, hemophilia b, clustered regularly interspaced short palindromic repeats, safety, hemorrhage, hemophilia a, blood coagulation factors, therapeutics | Phase 1/Phase 2 | Recruiting | 2025 |
| A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in People With Hemophilia A 2025-522434-32-00 — factor viii, safety, hemophilia a, pharmacokinetics | Phase 3 | Recruiting | 2026 |
| Study of Surgical Practices in Hemophilia A Patients Treated With Efanesoctocog Alfa (Altuvoct ) NCT07723560 — factor viii, hemorrhage, hemophilia a, research, therapeutics, child | N/A | Recruiting | 2026 |
| A research study looking at how different doses of study medicine (Inno8) work in the body of people with haemophilia A 2025-520490-38-00 — work, hemophilia a, research | Phase 1 | Not yet recruiting | 2025 |
LeadR Networks
Main global connection map